The EMMY trial represents an important step forward for SGLT2 inhibitors in the management of post-MI heart failure and supports the rapid expansion in indications for the use of SGLT2 inhibitors in a wide spectrum of HF. This evidence concerns the gene SLC5A2 and hydrops fetalis.